- Home
- MDXG
MDXG
MiMedx Group Inc
as 02-21-2025 4:00pm EST
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Upcoming Earnings Alert:
Get ready for potential market movements as MiMedx Group Inc MDXG prepares to release earnings report on 26 Feb 2025.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | MARIETTA |
| Market Cap: | 1.3B | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 493.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.47 - $10.14 | Next Earning Date: | 02-26-2025 |
| Revenue: | $342,804,000 | Revenue Growth: | 10.93% |
| Revenue Growth (this year): | 9.56% | Revenue Growth (next year): | 9.19% |
Latest MiMedx Group Inc News
MDXG Breaking Stock News: Dive into MDXG Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 days ago
MIMEDX to Host Fourth Quarter and Full Year 2024 Operating and Financial Results Conference Call on February 26
Simply Wall St.
17 days ago
While shareholders of MiMedx Group (NASDAQ:MDXG) are in the black over 3 years, those who bought a week ago aren't so fortunate
MT Newswires
2 months ago
MiMedx Files Patent Infringement Lawsuit Against Surgenex
Zacks
2 months ago
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?
GlobeNewswire
3 months ago
MIMEDX to Participate in Upcoming Investor Conferences
Simply Wall St.
3 months ago
Institutional investors own a significant stake of 43% in MiMedx Group, Inc. (NASDAQ:MDXG)
Zacks
3 months ago
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?
Zacks
3 months ago
How Much Upside is Left in MiMedx (MDXG)? Wall Street Analysts Think 37.12%
Compare MDXG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDXG MiMedx Group Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.